152 related articles for article (PubMed ID: 17909401)
1. Detection of darbepoetin alfa misuse in urine and blood: a preliminary investigation.
Morkeberg J; Lundby C; Nissen-Lie G; Nielsen TK; Hemmersbach P; Damsgaard R
Med Sci Sports Exerc; 2007 Oct; 39(10):1742-7. PubMed ID: 17909401
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
3. Identification of the long-acting erythropoiesis-stimulating agent darbepoetin alfa in human urine by liquid chromatography-tandem mass spectrometry.
Okano M; Sato M; Kageyama S
Anal Bioanal Chem; 2014 Feb; 406(5):1317-29. PubMed ID: 23443522
[TBL] [Abstract][Full Text] [Related]
4. Detection window of Darbepoetin-alpha following one single subcutaneous injection.
Lamon S; Robinson N; Mangin P; Saugy M
Clin Chim Acta; 2007 Apr; 379(1-2):145-9. PubMed ID: 17313941
[TBL] [Abstract][Full Text] [Related]
5. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
6. Detection of recombinant EPO in blood and urine samples with EPO WGA MAIIA, IEF and SAR-PAGE after microdose injections.
Dehnes Y; Shalina A; Myrvold L
Drug Test Anal; 2013; 5(11-12):861-9. PubMed ID: 24190107
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
13. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis.
Caldini A; Moneti G; Fanelli A; Bruschettini A; Mercurio S; Pieraccini G; Cini E; Ognibene A; Luceri F; Messeri G
Proteomics; 2003 Jun; 3(6):937-41. PubMed ID: 12833517
[TBL] [Abstract][Full Text] [Related]
15. Identification of darbepoetin alfa in human plasma by liquid chromatography coupled to mass spectrometry for doping control.
Guan F; Uboh CE; Soma LR; Birksz E; Chen J
Int J Sports Med; 2009 Feb; 30(2):80-6. PubMed ID: 19177313
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
17. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
18. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
19. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
Doshi S; Chow A; Pérez Ruixo JJ
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
